Molecular selectivity asks whether a compound prefers its intended target over other molecular targets. That question remains essential, but it does not by itself describe the physiological result of an intervention. Intended-target activity can extend across tissues, signalling conditions and functional states in ways that narrow a drug’s useful range.
A broader assessment of selectivity
Aeviant uses physiological selectivity internally as a working term for this broader evaluation. Publicly, the idea is straightforward: examine target preference together with biological state, timing, signalling bias, endogenous demand and functional consequence.
These are separate questions. A drug can have a clean binding profile while applying the intended mechanism in a state where that activity is unnecessary or harmful. Which dimensions matter, and whether state dependence is possible, depend on the mechanism being investigated.
What the framework does—and does not—claim
This is a research framework, not a demonstrated company capability and not a claim that every program will be state-dependent. Relevant criteria must be defined for each program and tested experimentally. Aeviant has not published experimental data establishing any form of physiological selectivity.